Rybrevant Faspro Wins Accelerated Approval for Advanced Head and Neck Cancer After 42% of Trial Patients Responded
The FDA approved Rybrevant Faspro through its accelerated pathway after 42% of 102 patients with advanced head and neck cancer responded in the OrigAMI-4 trial.
Medical Daily ·